Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

BioNexus Gene Lab (BGLC) Long-Term Debt Issuances (2019 - 2025)

BioNexus Gene Lab's Long-Term Debt Issuances history spans 5 years, with the latest figure at $15528.0 for Q1 2025.

Quarterly results put Long-Term Debt Issuances at $15528.0 for Q1 2025, down 24.06% from a year ago — trailing twelve months through Mar 2025 was $29979.0 (up 291.63% YoY), and the annual figure for FY2024 was $78835.0, down 94.42%.
Long-Term Debt Issuances for Q1 2025 was $15528.0 at BioNexus Gene Lab, down from $20448.0 in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $20448.0 in Q1 2024 to a low of -$8550.0 in Q1 2021.
The 3-year median for Long-Term Debt Issuances is -$5997.0 (2021), against an average of $2926.6.
The sharpest move saw Long-Term Debt Issuances plummeted 418.99% in 2021, then dropped 24.06% in 2025.
Year by year, Long-Term Debt Issuances stood at -$5997.0 in 2021, then soared by 440.97% to $20448.0 in 2024, then dropped by 24.06% to $15528.0 in 2025.
According to Business Quant data, Long-Term Debt Issuances over the past three periods came in at $15528.0, $20448.0, and -$5997.0 for Q1 2025, Q1 2024, and Q3 2021 respectively.